Dianthus Therapeutics (DNTH) Competitors $35.57 +3.77 (+11.86%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$35.94 +0.37 (+1.03%) As of 09/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. AMRX, XENE, KYMR, CRNX, RARE, MOR, BHC, NAMS, HCM, and GMTXShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), Bausch Health Cos (BHC), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors Amneal Pharmaceuticals Xenon Pharmaceuticals Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical MorphoSys Bausch Health Cos NewAmsterdam Pharma HUTCHMED Gemini Therapeutics AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability. Is AMRX or DNTH more profitable? AMNEAL PHARMACEUTICALS has a net margin of 0.12% compared to Dianthus Therapeutics' net margin of -2,364.56%. Dianthus Therapeutics' return on equity of -34.72% beat AMNEAL PHARMACEUTICALS's return on equity.Company Net Margins Return on Equity Return on Assets AMNEAL PHARMACEUTICALS0.12% -189.49% 6.17% Dianthus Therapeutics -2,364.56%-34.72%-32.72% Do analysts recommend AMRX or DNTH? AMNEAL PHARMACEUTICALS presently has a consensus price target of $11.60, suggesting a potential upside of 17.29%. Dianthus Therapeutics has a consensus price target of $60.67, suggesting a potential upside of 70.56%. Given Dianthus Therapeutics' higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than AMNEAL PHARMACEUTICALS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AMNEAL PHARMACEUTICALS 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, AMRX or DNTH? AMNEAL PHARMACEUTICALS has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Does the media refer more to AMRX or DNTH? In the previous week, Dianthus Therapeutics had 11 more articles in the media than AMNEAL PHARMACEUTICALS. MarketBeat recorded 22 mentions for Dianthus Therapeutics and 11 mentions for AMNEAL PHARMACEUTICALS. AMNEAL PHARMACEUTICALS's average media sentiment score of 1.09 beat Dianthus Therapeutics' score of 0.76 indicating that AMNEAL PHARMACEUTICALS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMNEAL PHARMACEUTICALS 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of AMRX or DNTH? 31.8% of AMNEAL PHARMACEUTICALS shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 17.5% of AMNEAL PHARMACEUTICALS shares are held by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, AMRX or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than AMNEAL PHARMACEUTICALS. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than AMNEAL PHARMACEUTICALS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAMNEAL PHARMACEUTICALS$2.79B1.11-$116.89M$0.01989.00Dianthus Therapeutics$4.85M235.87-$84.97M-$3.25-10.94 SummaryDianthus Therapeutics beats AMNEAL PHARMACEUTICALS on 8 of the 15 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02B$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.53%P/E Ratio-10.9421.3475.6926.28Price / Sales235.87471.32544.78188.18Price / CashN/A45.5837.2059.76Price / Book2.9910.0511.506.41Net Income-$84.97M-$53.33M$3.28B$270.56M7 Day Performance46.62%1.39%1.42%3.13%1 Month Performance89.61%11.91%11.28%9.74%1 Year Performance27.95%13.21%59.03%28.17% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics3.0917 of 5 stars$35.57+11.9%$60.67+70.6%+27.7%$1.02B$4.85M-10.9480Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeAMRXAmneal Pharmaceuticals3.035 of 5 stars$9.56+0.1%$11.60+21.3%+16.9%$3.00B$2.79B956.968,100Positive NewsXENEXenon Pharmaceuticals2.8073 of 5 stars$38.71+0.3%$53.20+37.4%-2.8%$2.98B$9.43M-10.90210Positive NewsKYMRKymera Therapeutics3.2172 of 5 stars$41.20-1.3%$58.76+42.6%-6.0%$2.95B$47.07M-11.87170Positive NewsCRNXCrinetics Pharmaceuticals3.8854 of 5 stars$30.99+1.1%$68.86+122.2%-30.1%$2.92B$1.04M-7.54210Positive NewsRAREUltragenyx Pharmaceutical4.3452 of 5 stars$29.96-1.1%$81.50+172.0%-43.5%$2.89B$560.23M-5.421,294Positive NewsAnalyst ForecastMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730BHCBausch Health Cos4.6782 of 5 stars$7.41+3.6%$9.00+21.5%+16.6%$2.75B$9.63B28.5020,700Positive NewsNAMSNewAmsterdam Pharma3.6207 of 5 stars$24.05+0.4%$41.55+72.7%+57.6%$2.71B$45.56M-14.854Positive NewsHCMHUTCHMED2.389 of 5 stars$15.01+1.2%$28.00+86.5%-7.2%$2.62B$630.20M0.001,811Analyst DowngradeGMTXGemini TherapeuticsN/A$59.650.0%N/A+23.0%$2.58BN/A-59.6530 Related Companies and Tools Related Companies Amneal Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Kymera Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Ultragenyx Pharmaceutical Alternatives MorphoSys Alternatives Bausch Health Cos Alternatives NewAmsterdam Pharma Alternatives HUTCHMED Alternatives Gemini Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
